Literature DB >> 18926443

Activin-A, transforming growth factor-beta, and myostatin signaling pathway in experimental dilated cardiomyopathy.

Maryam Mahmoudabady1, Myrielle Mathieu, Laurence Dewachter, Ielham Hadad, Lynn Ray, Pascale Jespers, Serge Brimioulle, Robert Naeije, Kathleen McEntee.   

Abstract

BACKGROUND: The pathogenic mechanisms of dilated cardiomyopathy are still uncertain. A number of cytokines and growth factors participate in the remodeling process of the disease.
METHODS: We investigated the cardiac myostatin, transforming growth factor (TGF)beta, and activin-A/Smad growth inhibitory signaling pathway in experimental dilated cardiomyopathy. Transvenous endomyocardial biopsies of the interventricular septum were taken weekly in 15 beagle dogs during the development of heart failure (HF) induced by rapid pacing over a period of 7 weeks. Genes involved in the myostatin-TGFbeta-activin-A/Smad signaling pathway and the cardiac hypertrophic process were quantified by real-time quantitative polymerase chain reaction. Left ventricular volume, function, and mass were evaluated by echocardiography.
RESULTS: Overpacing was associated with increased left ventricular volumes and decreased ejection fraction, whereas the left ventricular mass remained unchanged. TGFbeta was increased in moderate HF. Activin-A mRNA expression was 4-fold higher in overt congestive HF than at baseline. A 2-fold decrease of activin type II receptors and activin receptor interacting protein 2 gene expressions were observed, as well as a transient decrease of follistatin. Activin type I receptors, activin receptor interacting protein 1, follistatin-related gene, and myostatin remained unchanged. The inhibitory Smad 7, a negative feedback loop regulator of the Smad pathway, was overexpressed in severe HF. Gene expression of the cyclin-dependent kinase inhibitor p21, a direct target gene of the Smad pathway, was 8-fold up-regulated in HF, whereas cyclin D1 was down-regulated.
CONCLUSION: We conclude that tachycardia-induced dilated cardiomyopathy is characterized by gene overexpression of the TGFbeta-activin-A/Smad signaling pathway and their target gene p21 and by the absence of ventricular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18926443     DOI: 10.1016/j.cardfail.2008.05.003

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  15 in total

1.  The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells.

Authors:  Zuyue Sun; Jill Schriewer; Mingxin Tang; Jerry Marlin; Frederick Taylor; Ralph V Shohet; Eugene A Konorev
Journal:  J Mol Cell Cardiol       Date:  2015-12-11       Impact factor: 5.000

Review 2.  Myocardial adaptations in the failing heart: cause or consequence?

Authors:  Sabine J van Dijk; Nazha Hamdani; Ger J M Stienen; Jolanda van der Velden
Journal:  J Muscle Res Cell Motil       Date:  2009-02-14       Impact factor: 2.698

Review 3.  Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting.

Authors:  Astrid Breitbart; Mannix Auger-Messier; Jeffery D Molkentin; Joerg Heineke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-18       Impact factor: 4.733

4.  Association between transforming growth factor beta1 polymorphisms and atrial fibrillation in essential hypertensive subjects.

Authors:  Yongzheng Wang; Xuwei Hou; Yuliang Li
Journal:  J Biomed Sci       Date:  2010-03-31       Impact factor: 8.410

Review 5.  Tachycardia-mediated cardiomyopathy: recognition and management.

Authors:  Rakesh Gopinathannair; Renee Sullivan; Brian Olshansky
Journal:  Curr Heart Fail Rep       Date:  2009-12

6.  Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes.

Authors:  Kalyani D Panse; Leanne E Felkin; Marina M López-Olañeta; Jesús Gómez-Salinero; María Villalba; Lucía Muñoz; Kazuto Nakamura; Masayuki Shimano; Kenneth Walsh; Paul J R Barton; Nadia Rosenthal; Enrique Lara-Pezzi
Journal:  J Cardiovasc Transl Res       Date:  2012-08-23       Impact factor: 4.132

7.  Left ventricular global transcriptional profiling in human end-stage dilated cardiomyopathy.

Authors:  Dilek Colak; Namik Kaya; Jawaher Al-Zahrani; Albandary Al Bakheet; Paul Muiya; Editha Andres; John Quackenbush; Nduna Dzimiri
Journal:  Genomics       Date:  2009-03-28       Impact factor: 5.736

8.  Cardiac myocyte-specific ablation of follistatin-like 3 attenuates stress-induced myocardial hypertrophy.

Authors:  Masayuki Shimano; Noriyuki Ouchi; Kazuto Nakamura; Yuichi Oshima; Akiko Higuchi; David R Pimentel; Kalyani D Panse; Enrique Lara-Pezzi; Se-Jin Lee; Flora Sam; Kenneth Walsh
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

9.  Activin signaling as an emerging target for therapeutic interventions.

Authors:  Kunihiro Tsuchida; Masashi Nakatani; Keisuke Hitachi; Akiyoshi Uezumi; Yoshihide Sunada; Hiroshi Ageta; Kaoru Inokuchi
Journal:  Cell Commun Signal       Date:  2009-06-18       Impact factor: 5.712

10.  Cardiac insulin-like growth factor-1 and cyclins gene expression in canine models of ischemic or overpacing cardiomyopathy.

Authors:  Maryam Mahmoudabady; Myrielle Mathieu; Karim Touihri; Ielham Hadad; Agnes Mendes Da Costa; Robert Naeije; Kathleen Mc Entee
Journal:  BMC Cardiovasc Disord       Date:  2009-10-09       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.